Results 201 to 210 of about 239,934 (269)

The Effect of Efavirenz and Rufinamide on the Pharmacokinetics and Safety of Quizartinib: Two Phase 1 Studies in Healthy Participants. [PDF]

Clin Transl Sci
Yoo Y, Zahir H, Inaba S, Koo K, Garimella T, Abutarif M, Zheng M, Kamiyama E, Xu Y.   +8 more
europepmc   +1 more source

A Brain‐Penetrant Nanobody Reveals GSK3β‐Driven Proline‐Directed Phosphorylation as a Master Regulator of Ischemic Neurodegeneration

Advanced Science, EarlyView.
A brain‐targeted nanoparticle enables delivery of a therapeutic nanobody (Nb.29E9) that inhibits pathogenic GSK3β signaling. This intervention restores AMPK/mTORC1/TGFβ homeostasis, attenuates neuroinflammation and oxidative stress, and promotes long‐term functional recovery after ischemic stroke.
Lan Li, Muyang Li, Lei Sun, Ying Yang, Yuanshun Wu, Ziyi Yin, Anni Wang, Peiyang Zhou, Shaoxiang Luo, Jian Chen, Jun Qin, Zhibing Ai, Zilong Yuan, Zhiqiang Dong, Min Zhang   +14 more
wiley   +1 more source

Liposomal encapsulation of L-arginine and L-citrulline enhances pharmacokinetics and therapeutic effects in a model of preeclampsia and fetal growth restriction. [PDF]

Sci Rep
van Kammen C, Brink M, Minnion M, Feelisch M, Schiffelers R, Lely T, Terstappen F.   +6 more
europepmc   +1 more source

Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness. [PDF]

Clin Pharmacokinet
Wang Y, Bukkems LH, Ter Heine R, van Hasselt JGC, Koolen SLW, Hendrikx JJMA, Van der Hulle T, Kapiteijn E, Zwaveling J, Becker A, van den Heuvel MM, Theelen WSME, Oude Munnink TH, Smit EF, Guchelaar HJ, Moes DJAR.   +15 more
europepmc   +1 more source

Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat. [PDF]

Pharmacol Res Perspect
Sunnåker M, Leander J, Ericsson H.
europepmc   +1 more source

Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease. [PDF]

Saudi Pharm J
Drweesh H, Alotaibi A, Alqassim HA, Eid MM, Emsaad SA, Saad MO, Higazy AS, Alturaiki A, Almutairi F, Alhussain A, Assiri A, Alkofide H, Alruthia Y, Albassam A, Alsultan A.   +14 more
europepmc   +1 more source

Associations of CYP2B6, CYP2C19, and CYP2D6 isoforms and phenoconversion with sertraline pharmacokinetics. [PDF]

PLoS One
Tapia-Alzuguren B, Canga-Espina C, Molero P, Aldaz A.   +3 more
europepmc   +1 more source

Pharmacokinetics of Oral Amoxicillin for the Treatment of Syphilis in Pregnancy. [PDF]

Open Forum Infect Dis
Dionne JA, Subramaniam A, Kahn M, Xue Y, Ryan KJ, Acosta EP.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pharmacokinetics

Biochemical Pharmacology, 2014
Pharmacokinetics (PK) is the study of the time course of the absorption, distribution, metabolism and excretion (ADME) of a drug, compound or new chemical entity (NCE) after its administration to the body. Following a brief introduction as to why knowledge of the PK properties of an NCE is critical to its selection as a lead candidate in a drug ...
Jianghong, Fan, Inés A M, de Lannoy
openaire   +2 more sources

Lumping in Pharmacokinetics

Journal of Pharmacokinetics and Pharmacodynamics, 2005
Pharmacokinetic (PK) models simplify biological complexity by dividing the body into interconnected compartments. The time course of the chemical's amount (or concentration) in each compartment is then expressed as a system of ordinary differential equations.
Brochot, Céline, Toth, Janos, Bois, Frédéric Y.   +2 more
openaire   +4 more sources